Pharmacogenomics: the promise and reality of individualized treatment

Venue: Institut Pasteur

Location: Paris, France

Event Date/Time: Oct 17, 2002 End Date/Time: Oct 18, 2002
Early Registration Date: Sep 16, 2002
Paper Submission Date: Sep 16, 2002
Report as Spam

Description

THURSDAY OCTOBER 17, 2002

OPENING REMARKS
Welcome to the 2nd EUROCONFERENCE on Pharmacogenomics
Jeffrey M. Drazen, N.E.J.M., Boston, USA
B. Boris Vargaftig, Institut Pasteur, Paris, F

CANCER

Genetic polymorphisms and toxicity/response to cytotoxics
Mark J. Ratain, University of Chicago, USA

The clinical value of pharmacogenetics in Tamoxifen therapy
David A. Flockhart, Indiana University School of Medicine, Indianapolis, USA

Expression profiling: learning to search for things unappreciated
Stephen H. Friend, Rosetta Inpharmatics, Kirkland, USA

Gene expression profiles in diffuse large B-cell lymphoma
Margaret Shipp, Dana-Farber Cancer Institute, Boston, USA

Applications for protein and antibody arrays in pharmacoproteomics
Ian Humphery-Smith, Glaucus Proteomics, Bunnik, NL

ADVANCES IN GENOMICS OF CNS DISEASES

Pharmacogenomics of major depression and antidepressant treatment
Julio Licinio, University of California, Los Angeles, USA

Pharmacogenetic strategies in bipolar disorder
Gustavo Turecki, McGill University, Verdun, CDN

Genetic prediction of response and side effects from psychiatric medications
Vincenzo S. Basile, Mario Masellis & James L. Kennedy, University of Toronto, CDN

Advances in the pharmacogenetic prediction of antipsychotic response
Robert Kerwin, Institute of Psychiatry, London, UK

Pharmacogenomics and pharmacogenetics of Alzheimer's disease, toward new targets
Philippe Amouyel, Institut Pasteur de Lille, F

Pharmacogenetics in the therapy of epilepsy
Ulrich Brinkmann, Epidauros Biotechnologie, Bernried, D


FRIDAY OCTOBER 18, 2002


CARDIOVASCULAR DISEASES

Analytical strategies to understand how genetics contributes to common cardiovascular disorders
Fran├žois Cambien, INSERM U525/SC7, Paris, F

Gene-environment interaction in coronary artery disease
Steve E. Humphries, Royal Free & University College London Medical School, UK

Lipid lowering responses modified by genetic variation
Bernhard R. Winkelmann, University of Heidelberg, D

Antihypertensive pharmacogenetics
Stephen T. Turner, Mayo Clinic, Rochester, USA

Drug target pharmacogenomics: complexity of the drug response
Julie A. Johnson, University of Florida, Gainesville, USA

IMMUNOLOGY, ALLERGY, METABOLIC/OBESITY

Osteoporosis pharmacogenetics
John A. Eisman, Garvan Institute of Medical Research, Sydney, AUS

Pharmacogenetics of alcoholism and substance abuse
David Goldman, NIAAA, NIH, Rockville, USA

Pharmacogenomics in anesthesia and analgesia
Evan Kharash, University of Washington, Seattle, USA

Individualized treatment of obesity: fact or fiction?
Arya M. Sharma, University of Berlin, D

Genetically variable nicotine inactivation: potential role in smoking and therapeutic approaches
Rachel Tyndale, University of Toronto, CDN

Gene expression profiling in toxicology
Fran├žoise de Longueville, University of Namur, B

Venue

28 rue du Dr Roux
Paris
France
MORE INFO ON THIS VENUE

Types